BioArctic and Eisai team up on Alzheimer’s disease candidate BAN2802

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has entered into a new research evaluation agreement with Eisai Co., Ltd. The collaboration focuses on BAN2802, a potential Alzheimer’s disease treatment that integrates BioArctic’s proprietary BrainTransporter technology with an undisclosed Alzheimer drug candidate. At the conclusion of this evaluation phase, Eisai will review the data and determine whether to exercise an option to license BAN2802 for Alzheimer’s treatment.

This partnership underscores a long-standing collaboration between BioArctic and Eisai that dates back to 2005, primarily focusing on the development and commercialization of Alzheimer’s treatments. Their joint efforts have previously culminated in the development of Leqembi (lecanemab), recognized as the world’s first approved drug that demonstrably slows the progression of early Alzheimer’s disease.

Continued Partnership and Innovation in Alzheimer’s Treatment

The new agreement aims to leverage the extensive combined experience of both companies in Alzheimer’s therapy. The research evaluation will be jointly funded by BioArctic and Eisai and will explore what could be the next generation of disease-modifying treatments for Alzheimer’s disease.

“I am very happy that our Brain Transporter technology has continued to progress so well and that we have now entered into this first agreement utilizing this platform. I believe that this technology has huge potential to improve many different projects, and support companies in their pursuit of helping people with brain disorders,” expressed Gunilla Osswald, CEO of BioArctic. She added, “Eisai has been a valuable partner to BioArctic during the past two decades, and we are very pleased to extend and deepen our relationship with this new research evaluation agreement on BAN2802. Together, we have been able to deliver lecanemab, the first fully approved disease modifying treatment in Alzheimer’s disease in the US, Japan, and China, and we look forward to continuing our fruitful collaboration and lead the development of the next generation of drugs to help patients with this devastating disease.”

Exploring New Frontiers in Alzheimer’s Therapy

BioArctic’s BrainTransporter technology is designed to actively transport biologics across the blood-brain barrier, potentially enhancing the effectiveness and efficiency of treatments targeted at the brain. This innovation not only aims to improve clinical outcomes but also reduce the overall treatment burden on patients and healthcare systems. The technology reflects BioArctic’s commitment to sustainability by striving for continuous improvement in both clinical and commercial applications.

Future Outlook and Collaborative Impact

As the partnership progresses, BioArctic and Eisai will continue to focus on pioneering developments in Alzheimer’s treatment. The outcome of the BAN2802 evaluation could potentially lead to significant advancements in therapy for patients worldwide, emphasizing the importance of this ongoing collaboration in addressing complex neurological diseases.

This collaboration between BioArctic and Eisai highlights a pivotal moment in Alzheimer’s research, with potential implications that could reshape treatment paradigms and offer hope to millions affected by this challenging disease.